Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.48 USD | 0.00% | -3.31% | +0.47% |
05-14 | Wedbush Adjusts Voyager Therapeutics' PT to $8 From $10, Keeps Neutral Rating | MT |
05-13 | Transcript : Voyager Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.47% | 461M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- VYGR Stock
- News Voyager Therapeutics, Inc.
- Voyager Therapeutics : Wedbush Cuts Voyager Therapeutics to Neutral From Outperform, PT to $6 From $13 as Neurocrine Biosciences Ends Gene Therapy Collaboration